Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retosiban
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Retosiban is a small molecule oxytocin receptor antagonist developed by GlaxoSmithKline for the management of preterm labor. It is an orally and intravenously administered drug that selectively blocks the oxytocin receptor, with over 1400-fold selectivity compared to vasopressin receptors. Retosiban acts as an inverse agonist at the oxytocin receptor, reducing both spontaneous and stretch-induced uterine contractions in preclinical models and human myometrial tissue. Clinical studies have shown that retosiban can prolong pregnancy in women experiencing spontaneous preterm labor, with a favorable safety profile observed in phase I–III trials. Despite promising results, development for this indication has been discontinued after phase III trials[1][3][4][5][8].
- Other names
- retosiban820957-38-8
02
Targets
Oxytocin receptor
Beyond the preview
Go deeper on retosiban.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retosiban.